Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Antoniou, G. Margaritopoulos, S. R. Desai, D. Hansell, M. Rubens, R. C. Tennant, T. T. Hansel, N. Siafakas, R. DuBois, A. Wells (Heraklion Crete, London, Greece). Pulmonary fibrosis is associated with emphysema in systemic sclerosis: indirect support for a smoking pathogenesis hypothesis. Eur Respir J 2009; 34: Suppl. 53, 2821

Member's Comments

No comment yet.

Related content which might interest you: Associations between emphysema and pulmonary fibrosis are suggestive of a smoking pathogenesis common to both disorders Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis Year: 2008 Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease Source: Eur Respir Rev, 27 (148) 170102; 10.1183/16000617.0102-2017 Year: 2018 Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin Source: Eur Respir J 2001; 18: 17S-29S Year: 2001 Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Source: Eur Respir J 2007; 30: 835-839 Year: 2007 Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome Source: Eur Respir J 2010; 35: 105-111 Year: 2010 Systemic inflammation in patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Pulmonary function in smoking and systemic inflammation Source: Annual Congress 2009 - Tobacco: from smoke to disease Year: 2009 Inflammation in COPD: a link to systemic comorbidities Source: Eur Respir Rev 2007; 16: 91-97 Year: 2007 Systemic autoimmunity and  pulmonary fibrosis Source: International Congress 2017 – GR3 Scientific Grand Round: Autoimmunity in chronic lung disease Year: 2017 Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 A proof of concept study by thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Oxygen pulse slope analysis during exercise testing identifies patients with systemic sclerosis at a possible risk for developing pulmonary vasculopathy Source: Annual Congress 2013 –Clinical exercise physiology Year: 2013 Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease Source: Eur Respir J, 53 (5) 1802182; 10.1183/13993003.02182-2018 Year: 2019 The association between bronchiectasis and systemic inflammation Source: International Congress 2019 – Bronchiectasis Year: 2019 Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Association of FVC/DLCO with pulmonary hypertension risk and interstitial disease in systemic sclerosis patients Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Occupational risk factors and idiopathic pulmonary fibrosis. A case-control study Source: Annual Congress 2007 - The air we breathe at home and at work Year: 2007 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016